At a glance
ClinicalIndex Comparison RecordN/ACompleted· 36 enrolled
Drug / intervention
Placebo +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Targeting ADAM17 Activity for Correction of Vascular Insulin Resistance in Type 2 Diabetes
In Brief
A clinical study evaluating Placebo and Phosphatidylserine for Diabetes Mellitus, Type 2. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The objective of this project is to determine the extent to which administration of the dietary supplement phosphatidylserine (PS), a competitive inhibitor of ADAM17 sheddase activity, effects vascular function and insulin-stimulated leg blood flow in subjects with T2D.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartMar 2023
Primary CompletionFeb 2025
Study CompletionNov 2025
TodayJul 2026
First PostedSep 21, 2020
Enrollment StartMar 1, 2023
Primary CompletionFeb 3, 2025
Study CompletionNov 1, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.8 years ago
Interventions
Placebodietary
4 weeks of placebo supplements
Phosphatidylserinedietary
4 weeks of phosphatidylserine supplements